### Case Series Drug Analysis Print Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021

Data Lock Date: 08-Apr-2021 18:30:03

Earliest Reaction Date: 08-Nov-1999 MedDRA 23.1 MedDRA Version:

FOI 21/590 -All UK, suspected spontaneous reports associated Menjugate Product Analysis Print: with Menjugate up to and including 08/04/2021

Report Run Date: 29-Jun-2021, Page 1

Reaction Name	Total	Fatal
Blood disorders		
Coagulopathies		
Coagulopathy	1	0
Lymphatic system disorders NEC		
Lymphadenopathy	7	0
Thrombocytopenias		
Immune thrombocytopenia	2	0
Thrombocytopenia	1	0
Blood disorders SOC TOTAL	11	0

Reaction Name	Total	Fatal
Cardiac disorders		
Cardiac disorders NEC		
Cardiovascular disorder	2	0
Cardiac signs and symptoms NEC		
Palpitations	3	0
Rate and rhythm disorders NEC		
Arrhythmia	1	0
Bradycardia	12	0
Tachycardia	9	0
Cardiac disorders SOC TOTAL	27	0

Name: FOI 21/590 - Menjugate Product Analysis Print

Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03

action Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1 Report Run Date: 29-Jun-2021 Earliest Reaction Date: 08-Nov-1999

Reaction Name	Total	Fatal
Congenital disorders		
Cardiac septal defects congenital		
Atrial septal defect	1	0
Congenital disorders SOC TOTAL	1	l o

Report Run Date: 29-Jun-2021, Page 4

Reaction Name	Total	Fatal
Ear disorders		
Ear disorders NEC		
Ear pain	6	0
Hearing losses		
Deafness transitory	2	0
Hypoacusis	4	0
Inner ear signs and symptoms		
Tinnitus	11	0
Vertigo	2	0
Ear disorders SOC TOTAL	25	0

Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1	.50.05	
Reaction Name	Total	Fatal
Eye disorders		
Glaucomas (excl congenital)		
Glaucoma	1	0
Lid, lash and lacrimal infections, irritations and inflammations		
Swelling of eyelid	1	0
Ocular disorders NEC		
Eye disorder	1	0
Eye pain	11	0
Eye swelling	8	0
Periorbital oedema	2	0
Ocular infections, inflammations and associated manifestations		
Eye irritation	1	0
Eye pruritus	2	0
Ocular nerve and muscle disorders		
Eye movement disorder	13	0
Ocular sensation disorders		
Abnormal sensation in eye	1	0
Photophobia	20	0
Pupil disorders		
Mydriasis	5	0
Pupils unequal	2	0
Visual disorders NEC		
Diplopia	10	0
Photopsia	6	0
Vision blurred	46	0
Visual impairment and blindness (excl colour blindness)		
Blindness transient	4	0
Visual impairment	6	0
Eve disorders SOC TOTAL	140	0

Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedD	RA 23.1	
Reaction Name	Total	Fatal
Gastrointestinal disorders		
Diarrhoea (excl infective)		_
Diarrhoea	27	0
Dyspeptic signs and symptoms		_
Dyspepsia	1	0
Flatulence, bloating and distension		
Abdominal distension	1	0
Gastrointestinal and abdominal pains (excl oral and throat)		
Abdominal pain	84	0
Abdominal pain upper	102	0
Gastrointestinal atonic and hypomotility disorders NEC		_
Constipation	1	0
Gastrointestinal signs and symptoms NEC		_
Abdominal discomfort	8	0
Dysphagia	5	0
Gingival disorders, signs and symptoms NEC		_
Gingival pain	1	0
Nausea and vomiting symptoms		
Nausea	644	0
Retching	4	0
Vomiting	383	0
Vomiting projectile	1	0
Oral dryness and saliva altered		
Dry mouth	1	0
Salivary hypersecretion	3	0
Oral soft tissue signs and symptoms		
Hypoaesthesia oral	1	0
Lip pain	1	0
Oral soft tissue swelling and oedema		
Lip swelling	5	0
Stomatitis and ulceration		
Mouth ulceration	1	0
Tongue signs and symptoms		
Swollen tongue	2	0
Gastrointestinal disorders SOC TOTAL	1276	0

Earliest Reaction Date: 08-Nov-1999	MedDRA Version: MedDRA 23.1	
Reaction Name	Total	<u> Fatal</u>
General disorders		
Adverse effect absent		
No adverse event	1	0
Asthenic conditions		
Asthenia	44	I 0
Fatigue	87	7 0
Malaise	428	3 <b> </b> 0
Sluggishness	1	ıl ol
Death and sudden death		
Sudden death		1
Febrile disorders		
Hyperpyrexia	1	l ol
Pyrexia	271	_
Feelings and sensations NEC		
Chills	45	o
Feeling abnormal		. 1
Feeling cold	36	
Feeling drunk	1	اً ا
Feeling hot	125	_
Feeling of body temperature change	23	
Gait disturbances		Ί Ϋ
Gait disturbance	6	s o
General signs and symptoms NEC		Ί
Condition aggravated		2 0
Crepitations		
Crying	29	·   •
	25	
High-pitched crying Illness	30	·   •
Influenza like illness	24	
Local reaction	209	
	369	
Peripheral swelling	11	
Screaming		
Swelling	84	
Swelling face Inflammations		0
	E	
Inflammation	53	9 0
Injection site reactions	-	
Injection site erythema	5	
Injection site haemorrhage	405	0
Injection site inflammation	125	
Injection site mass	2	-
Injection site pain	33	
Injection site rash	21	
Injection site reaction	187	
Injection site swelling	3	9 0
Oedema NEC		
Face oedema		0
Generalised oedema		0
Localised oedema		0
Oedema	1	0
Oedema peripheral	10	
Pain and discomfort NEC		
Axillary pain	1	-
Chest discomfort	22	2 0

Reaction Name	Total	Fatal
General disorders General disorders cont'd		
Chest pain	18	0
Discomfort	6	0
Pain	47	0
Tenderness	12	0
Therapeutic and nontherapeutic responses		
Drug ineffective	1	0
Vaccination site reactions		
Vaccination site pain	4	0
General disorders SOC TOTAL	2403	1

Reaction Name	Total	Fatal
Immune system disorders		
Allergic conditions NEC		
Hypersensitivity	11	0
Allergies to foods, food additives, drugs and other chemicals		
Reaction to excipient	1	0
Anaphylactic and anaphylactoid responses		
Anaphylactic reaction	18	0
Anaphylactic shock	4	0
Anaphylactoid reaction	2	0
Immune system disorders SOC TOTAL	36	0

Reaction Name	Total	Fatal
Infections		
Bacterial infections NEC		
Bacterial infection	1	0
Cellulitis	5	0
Injection site cellulitis	1	0
Bordetella infections		
Pertussis	1	0
Central nervous system and spinal infections		
Meningitis	2	1
Ear infections		
Ear infection	2	0
Eye and eyelid infections		
Hordeolum	1	0
Herpes viral infections		
Oral herpes	1	0
Varicella	1	0
Infections NEC		
Infection	3	0
Injection site abscess	2	0
Localised infection	1	0
Vaccination site abscess	2	0
Lower respiratory tract and lung infections		
Lower respiratory tract infection	1	0
Neisseria infections		
Meningitis meningococcal	8	0
Meningococcal infection	10	0
Meningococcal sepsis	2	0
Sepsis, bacteraemia, viraemia and fungaemia NEC		
Sepsis	1	0
Skin structures and soft tissue infections		
Rash pustular	1	0
Streptococcal infections		
Pneumococcal infection	2	0
Tuberculous infections		
Erythema induratum	11	0
Upper respiratory tract infections		
Nasopharyngitis	27	0
Pharyngitis	3	0
Tonsillitis	2	0
Upper respiratory tract infection	1	0
Viral infections NEC		
Viral infection	1	0
Infections SOC TOTAL	93	1

Reaction Name	Total	Fatal
Injuries		
Fractures and dislocations NEC		
Joint dislocation	1	0
Non-site specific injuries NEC		
Fall	3	0
Overdoses NEC		
Overdose	2	0
Product administration errors and issues		
Inappropriate schedule of product administration	1	0
Wrong product administered	1	0
Skin injuries NEC		
Contusion	5	0
Vaccination related complications		
Vaccination complication	1	0
Vaccination failure	20	0
Injuries SOC TOTAL	34	0

### Case Series Drug Analysis Print Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03
Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1		
Reaction Name	<u>  Total                                    </u>	<u>Fatal</u>
Investigations		
Blood gas and acid base analyses		
Oxygen saturation decreased	2	0
Carbohydrate tolerance analyses (incl diabetes)		
Blood glucose decreased	1	0
Heart rate and pulse investigations		
Heart rate decreased	12	0
Heart rate increased	16	0
Heart rate irregular	3	0
Pulse abnormal	28	0
Pulse absent	1	0
Immunology analyses NEC		
Tryptase increased	1	0
Neurologic diagnostic procedures		
Electroencephalogram abnormal	1	0
Physical examination procedures and organ system status		
Body temperature	10	0
Body temperature increased	36	0
Respiratory rate decreased	1	0
Respiratory rate increased	2	0
Weight decreased	1	0
Platelet analyses		
Platelet count decreased	1	0
Protein analyses NEC		
C-reactive protein increased	1	0
Red blood cell analyses		
Haemoglobin decreased	1	0
Renal function analyses		
Blood creatinine decreased	1	0
Blood urea decreased	1	0
Vascular tests NEC (incl blood pressure)		
Blood pressure decreased	7	0
Blood pressure increased	2	0
Investigations SOC TOTAL	129	0

Reaction Name	Total	Fatal
Metabolic disorders		
Appetite disorders		
Decreased appetite	13	0
Hypophagia	1	0
Diabetes mellitus (incl subtypes)		
Diabetes mellitus inadequate control	2	0
Type 1 diabetes mellitus	1	0
Food malabsorption and intolerance syndromes (excl sugar intolerance)		
Dairy intolerance	1	0
Food intolerance	1	0
General nutritional disorders NEC		
Feeding disorder	2	0
Food aversion	1	0
Poor feeding infant	3	0
Hypoglycaemic conditions NEC		
Hypoglycaemia	1	0
Metabolic disorders SOC TOTAL	26	0

Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03
Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Earliest Reaction Date: 08-Nov-1999	MedDRA Version: MedDRA 23.1		
Reaction Name		Total	Fatal
Muscle & tissue disorders			
Joint related disorders NEC			
Hypermobility syndrome		1	0
Joint related signs and symptoms			
Arthralgia		27	0
Joint stiffness		3	0
Joint swelling		1	0
Muscle pains			
Myalgia		23	0
Muscle related signs and symptoms NE	C		
Muscle disorder		2	0
Muscle spasms		4	0
Muscle twitching		52	0
Muscle tone abnormalities			
Floppy infant		2	0
Muscle rigidity		22	0
Muscle weakness conditions			
Muscular weakness		18	0
Musculoskeletal and connective tissue of	conditions NEC		
Musculoskeletal stiffness		65	0
Toe walking		1	0
Musculoskeletal and connective tissue	pain and discomfort		
Back pain		18	0
Limb discomfort		8	0
Neck pain		31	0
Pain in extremity		270	0
Spondyloarthropathies			
Arthritis reactive		1	0
Synovial disorders			
Synovitis		1	0
Muscle & tissue disorders SOC TOTAL		550	0

Name: FOI 21/590 - Menjugate Product Analysis Print

		.,	
Report Run Date: 29-Jun-2021	Data Lock Date: 08-Apr-2021	18:30:03	
Earliest Reaction Date: 08-Nov-1999	MedDRA Version: MedDRA 23	3.1	
Reaction Name		Total	Fatal
Neoplasms			
Cardiovascular neoplasms benign			
Haemangioma		1	0
Nervous system neoplasms unspect	ified malignancy NEC		
Astrocytoma		1	0
Skin neoplasms benign			
Haemangioma of skin		1	0
Skin neoplasms malignant and unsp	pecified (excl melanoma)		
Neoplasm skin	,	2	0
Neoplasms SOC TOTAL		5	o

	MedDRA Version: MedDRA 23.1	Fatal
Reaction Name	Total	<u>Fatal</u>
Nervous system disorders		
Absence seizures		
Petit mal epilepsy	6	0
Acute polyneuropathies		
Guillain-Barre syndrome	1	0
Coordination and balance disturbances		
Balance disorder	6	1
Coordination abnormal		_
Dysstasia	2	
Hand-eye coordination impaired	1	0
Cortical dysfunction NEC		
Dyspraxia	1	0
Disturbances in consciousness NEC		_
Depressed level of consciousness	2	2 0
Lethargy	33	1
Loss of consciousness	30	
Somnolence	92	1
Stupor	1	0
Syncope	590	0
Dyskinesias and movement disorders NEC		
Dyskinesia	27	1
Hypokinesia	1	0
Psychomotor hyperactivity		0
Dystonias		
Dystonia	1	-
Opisthotonus		0
Facial cranial nerve disorders		
Facial paralysis		0
Generalised tonic-clonic seizures		
Generalised tonic-clonic seizure	13	0
Headaches NEC		
Headache	1091	0
Hydrocephalic conditions		
Hydrocephalus		0
Increased intracranial pressure disorders		
Idiopathic intracranial hypertension		0
Mental impairment (excl dementia and memor	ry loss)	
Cognitive disorder		
Disturbance in attention	3	0
Migraine headaches		
Migraine	4	1
Migraine with aura		0
Muscle tone abnormal		
Hypotonia	9	0
Neurological signs and symptoms NEC		
Dizziness		
Fontanelle bulging	1	0
Grimacing		0
Meningism	2	1
Neurological symptom	1	0
Presyncope	28	1
Unresponsive to stimuli	2	2 0
Neuromuscular disorders NEC		
Muscle spasticity	1	0

Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Reaction Name	Total	Fatal
Nervous system disorders us system disorders cont'd		
Paraesthesias and dysaesthesias		
Burning sensation		2 0
Hyperaesthesia	Ę	5 0
Hypoaesthesia	48	3 0
Paraesthesia	57	7 0
Partial complex seizures		
Focal dyscognitive seizures	•	1 0
Seizures and seizure disorders NEC		
Epilepsy	11	1 0
Seizure	52	2 0
Seizure anoxic	į (	0
Status epilepticus		1 0
Sensory abnormalities NEC		
Dysgeusia		1 0
Sensory disturbance	•	1 0
Sleep disturbances NEC		
Poor quality sleep	•	1 0
Speech and language abnormalities		
Dysarthria	2	2 0
Speech disorder		2 0
Tremor (excl congenital)		
Tremor	45	5 0
Nervous system disorders SOC TOTAL	3307	7 o

## Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03
Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Reaction Name	<u>Total</u>	Fatal
Product quality issues NEC		
Product complaint	1	0
null SOC TOTAL	1	ıl ol

## Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03
Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1		
Reaction Name	_ Total_	<u>Fatal</u>
Psychiatric disorders		
Abnormal behaviour NEC		
Abnormal behaviour	2	0
Staring	3	0
Anxiety symptoms		
Agitation	4	0
Anxiety	8	0
Nervousness	24	0
Tension	1	0
Behaviour and socialisation disturbances		
Aggression	2	0
Confusion and disorientation		
Confusional state	3	0
Disorientation	7	0
Deliria		
Delirium	6	0
Disturbances in initiating and maintaining sleep		
Insomnia	2	0
Eating disorders NEC		
Selective eating disorder	1	0
Emotional and mood disturbances NEC		
Emotional distress	5	0
Emotional poverty	1	0
Irritability	13	0
Mood altered	2	0
Fear symptoms and phobic disorders (incl social phobia)		
Social fear	1	0
Fluctuating mood symptoms		
Mood swings	1	0
Hallucinations (excl sleep-related)		
Hallucination	6	0
Increased physical activity levels		
Restlessness	2	0
Mood alterations with depressive symptoms		
Depressed mood	2	0
Tearfulness	6	0
Obsessive-compulsive disorders and symptoms		
Obsessive-compulsive symptom	1	0
Panic attacks and disorders		
Panic attack	3	0
Panic reaction	3	0
Pervasive developmental disorders NEC		
Autism spectrum disorder	1	0
Psychiatric elimination disorders		
Enuresis	1	0
Sleep disorders NEC		
Sleep disorder	2	0
Speech articulation and rhythm disturbances		
Lack of spontaneous speech	1	0
Tic disorders		
Tic	1	0
Psychiatric disorders SOC TOTAL	115	

Reaction Name	Total	Fatal
Renal & urinary disorders		
Bladder and urethral symptoms		
Incontinence	3	0
Urinary incontinence	7	0
Glomerulonephritis and nephrotic syndrome		
Glomerulonephritis membranoproliferative	1	0
Nephrotic syndrome	1	0
Urinary abnormalities		
Haematuria	1	0
Renal & urinary disorders SOC TOTAL	13	0

## Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03
Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Reaction Name	Total	Fatal
Reproductive & breast disorders		
Reproductive tract signs and symptoms NEC		
Oedema genital	1	0
Reproductive & breast disorders SOC TOTAL	1	l ol

Name: FOI 21/590 - Menjugate Product Analysis Print

Report Run Date: 29-Jun-2021 Data Lock Date: 08-Apr-2021 18:30:03

Earliest Reaction Date: 08-Nov-1999 MedDRA Version: MedDRA 23.1

Reaction Name	Total	Fatal
Respiratory disorders		
Breathing abnormalities		
Apnoea	2	0
Dyspnoea	24	0
Hyperventilation	18	0
Hypopnoea	1	0
Respiratory arrest	1	0
Respiratory distress	1	0
Bronchospasm and obstruction		
Asthma	5	0
Bronchospasm	3	
Wheezing	6	0
Conditions associated with abnormal gas exchange		
Cyanosis central	2	0
Coughing and associated symptoms		
Cough	12	0
Laryngeal spasm, oedema and obstruction		
Laryngospasm	1	0
Stridor	2	0
Nasal congestion and inflammations		
Nasal congestion	1	0
Nasal disorders NEC		
Epistaxis	5	0
Paranasal sinus disorders (excl infections and neoplasms)		
Sinus congestion	1	0
Pharyngeal disorders (excl infections and neoplasms)		
Pharyngeal oedema	1	0
Pharyngeal swelling	5	0
Respiratory tract disorders NEC		
Respiratory disorder	1	0
Upper respiratory tract signs and symptoms		
Choking	2	0
Dry throat	2	0
Nasal discomfort	1 1	0
Oropharyngeal pain	47	0
Rhinorrhoea	2	0
Throat irritation	6	0
Throat tightness	17	0
Respiratory disorders SOC TOTAL	169	

Earliest Reaction Date: 08-Nov-1999	MedDRA Version: MedDRA 23.1	T-(-1	F-1-1
Reaction Name		Total	Fatal
Skin disorders			
Angioedemas		•	•
Angioedema		2	0
Apocrine and eccrine gland disorders			_
Cold sweat		148	0
Hyperhidrosis		112	0
Miliaria		1	0
Bullous conditions			
Blister		6	0
Erythema multiforme		4	0
Dermal and epidermal conditions NEC			
Dry skin		1	0
Macule		2	0
Pain of skin		17	0
Skin burning sensation		1	0
Skin discolouration		10	0
Skin discomfort		1	
Skin induration		13	0
Skin lesion		1	
Skin reaction		9	0
Dermatitis and eczema			
Dermatitis allergic		2	0
Eczema		3	0
Eczema infantile		1	0
Skin irritation		2	0
Erythemas			
Erythema		249	0
Pruritus NEC			
Pruritus		38	0
Purpura and related conditions			
Petechiae		16	0
Purpura		9	0
Rashes, eruptions and exanthems NEC			
Rash		129	0
Rash erythematous		16	0
Rash macular		50	0
Rash maculo-papular		4	0
Rash papular		2	0
Rash pruritic		17	0
Rash rubelliform		1	0
Rash vesicular		2	0
Skin vasculitides			
Capillaritis		1	0
Skin vasomotor conditions			
Livedo reticularis		6	0
Urticarias			
Urticaria		51	0
Urticaria pigmentosa		1	0
Skin disorders SOC TOTAL		928	

Reaction Name	Total	Fatal
Social circumstances		
Disability issues		
Immobile	2	0
Social circumstances SOC TOTAL	2	0

Reaction Name	Total	Fatal
Surgical & medical procedures		
Induced abortions		
Abortion induced	1	0
Surgical & medical procedures SOC TOTAL	1	0

Reaction Name	Total	Fatal
Vascular disorders		
Circulatory collapse and shock		
Circulatory collapse	25	0
Shock	6	0
Haemorrhages NEC		
Haemorrhage	1	0
Peripheral vascular disorders NEC		
Cyanosis	25	0
Flushing	59	0
Peripheral vasoconstriction, necrosis and vascular insufficiency		
Peripheral coldness	14	0
Peripheral ischaemia	1	0
Vasoconstriction	2	0
Site specific vascular disorders NEC		
Pallor	454	0
Vascular hypotensive disorders		
Hypotension	10	0
Vascular disorders SOC TOTAL	597	0
TOTAL REACTIONS FOR DRUG	9890	2
TOTAL REPORTS	4479	
TOTAL FATAL OUTCOME REPORTS		2